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Natural killer T (NKT) cells have gained great attention owing to their critical functional
roles in immunity to various pathogens. In this review, we provide an overview of the
current knowledge on the role of NKT cells in host defense against and pathogenesis
due to Chlamydia, which is an intracellular bacterial pathogen that poses a threat to
the public health worldwide. Accumulating evidence has demonstrated that NKT cells,
particularly invariant NKT (iNKT) cells, play a crucial role in host defense against chlamydial
infections, especially inC. pneumoniae infection. iNKT cells can promote type-1 protective
responses to C. pneumoniae by inducing enhanced production of IL-12 by dendritic
cells (DCs), in particular CD8α+ DCs, which promote the differentiation of naive T
cells into protective IFN-γ-producing Th1/Tc1 type CD4+/CD8+ T cells. This iNKT-cell-
mediated modulation of DC function is largely dependent upon CD40–CD40L interaction,
IFN-γ production, and cell-to-cell contact. In addition, iNKT cells modulate the function of
natural killer cells. NKT cells may be also involved in the pathogenesis of some chlamydial
diseases by inducing different patterns of cytokine production. A better understanding of
NKT-cell biology will enable us to rationally design prophylactic and therapeutic tools to
combat infectious diseases.
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Introduction
Natural killer T (NKT) cells represent a unique population of innate lymphocytes that express
the natural killer (NK)- and T-cell markers, such as NK1.1 and αβ T-cell receptor (TCR) (1).
NKT cells are divided into two subsets, type I or invariant NKT (iNKT) and type II NKT cells,
depending upon their TCR forms and cognate ligands. iNKT cells possess the invariant αβ
TCR (iTCR) that recognizes glycolipid and lipid antigens presented to them by CD1d molecules.
iNKT cells are the most widely studied subset of NKT cells. Activation of iNKT cells leads
to the rapid production of Th1, Th2, and Th17 cytokines and chemokines (2). On the other
hand, type II NKT cells do not express the iTCR and are reactive to sulfatides (1). Because of
their distinct immunologic characteristics and crucial functions in host immune responses to
different pathogens, NKT cells have gained much attention in recent years (3). In this review, we
focus on the functional role of NKT cells, especially iNKT cells, in conferring T-cell immunity
against chlamydiae, which are obligate intracellular bacteria that cause a range of human diseases
worldwide (4). In particular, we describe how iNKT cells bridge innate and adaptive immunity
by modulating the function of dendritic cells (DCs) during chlamydial infection. These findings
Abbreviations: Ag, antigen; C, Chlamydia; CD40L, CD40 ligand; DC, dendritic cell; IC, infected cell; IL-12, interleukin-12;
iNKT, invariant natural killer T cell; iTCR, invariant T cell receptor; Tc, CD8+ T cytotoxic cell; Th1, T helper cell.
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present a rational basis for developing effective prophylactics and
therapeutics against infectious diseases.
Chlamydial Infections and
Their Pathophysiology
Chlamydia has a biphasic life cycle, consisting of two distinct
forms, elementary body (EB) and reticulate body (RB). EB is an
extracellular and metabolically inactive, but stable form, which
is responsible for dissemination of infection from one person to
another. On the contrary, RB is an intracellular and metabolically
active form (5). EBs attach and enter the epithelial cells through
endocytosis. Following their entry into the cell, the EBs undergo
germination to give rise to RBs. The RBs so formed multiply by
binary fission in enlarging vacuoles called inclusion bodies. As
the inclusion body expands following maturation, the RBs re-
differentiate into EBs, which are released by the cells to infectmore
cells (6).
Chlamydial species belong to the taxonomic family Chlamydi-
aceae. Using 16s and 23s rRNA sequencing, the family Chlamy-
diaceae has divided into two genera and nine species (7). Out of
these nine chlamydial species, C. trachomatis and C. pneumoniae
(also called as Chlamydophila pneumoniae) are clinically signifi-
cant species that cause a variety of human diseases. C. trachomatis
has three human serovars, including serovars A–C, D–K, and
L1–L2. Serovars D–K of C. trachomatis are the most common
cause of bacterial sexually transmitted diseases (STDs), but can
also cause neonatal pneumonia and conjunctivitis (4, 8–11). They
cause 90 million cases of STDs each year across the globe, with
approximately 3 million cases alone in the United States (11). The
clinical manifestations of chlamydial genital infection in women
include urethritis, cervicitis, upper genital tract infection, and
perihepatitis. If untreated, infected women can develop pelvic
inflammatory disease, which have serious consequences, such as
infertility, ectopic pregnancy, and abortion. In men, C. trachoma-
tis infection can cause urethritis, epididymitis, seminal vesiculitis,
and prostatitis (8, 9). It is notable here that majority of infected
people are asymptomatic and only about 20% of infected women
and 30% ofmen show clinical signs of chlamydial infection and so
are subjected to antibiotic treatment. A range of broad spectrum
antibiotics such as erythromycin and tetracycline are effective
against Chlamydia, although an accurate and timely diagnosis of
chlamydial infections presents a challenge to the clinician due
to their diverse clinical manifestations (4, 12). Serovars L1–L2
of C. trachomatis cause lymphogranuloma venereum, which is a
venereal disease with lesions in genital tissues, particularly the
tissue-draining lymphatics and lymph nodes. These genital tract
chlamydial infection increases the chance of women to be infected
with human immunodeficiency virus andhumanpapilloma virus-
induced cervical neoplasia (13, 14). Apart from genital tract infec-
tion, serovars A–C of C. trachomatis cause trachoma, which is
the leading cause of infectious blindness worldwide that affects
about 84 million people with active disease. Pathologic lesions
in trachoma include the development of follicles and inflamed
conjunctivae that lead to cloudy and vascularized cornea, trichi-
asis, corneal ulcer, and blindness. Transmission of C. trachomatis
for trachoma takes place by contaminated fingers or fomites or
through placenta in infected mothers (15, 16). On the other hand,
C. pneumoniae causes a variety of respiratory diseases, including
sinusitis, pharyngitis, bronchitis, and community-acquired pneu-
monia that are common throughout the world (17). A higher
prevalence of chlamydial infection is however noted in thirdworld
countries compared to the developed ones. Humans are the only
known reservoir for C. pneumoniae. In recent years, there are var-
ious reports based on epidemiological, immunological, and phar-
macological studies that indicate an association of C. pneumoniae
infection with cardiovascular and neurodegenerative diseases,
such as atherosclerosis, Alzheimer’s disease, andmultiple sclerosis
(18–20). Despite considerable efforts, it still remains a challenge
to develop a safe and effective chlamydial vaccine due to inade-
quate knowledge of protective immunity and immunopathology
of chlamydial infections. This is important because of the fact
that the immune responses also contribute to the pathogenesis of
chlamydial diseases (21). An effective vaccine strategy therefore
requires the identification of antigens/adjuvants, which evoke
protective but not pathologic immune responses.
Coexistence of Chlamydia and its host imposes an evolution-
ary pressure on both of them. The host’s immune system has
developed to defend the body from chlamydial infections, whereas
chlamydiae are equipped with various evasion mechanisms to
escape the host’s immune system. Pathogenesis of chlamydial dis-
eases is the result of this host–pathogen interaction. Chlamydial
infection leads to the activation of mucosal epithelial cells. Activa-
tion of epithelial cells induces secretion of multiple cytokines and
chemokines, such as IL-1, TNF-α, IL-8, GM-CSF, and IL-6, which
cause infiltration of immune cells at the primary site of infec-
tion. These immune cells include, but not limited to, neutrophils,
monocytes, NK cells, and T cells. Infected epithelial cells and
neutrophils secrete potent proteolytic enzymes like elastase and
MMPs to cause tissue damage (22–24). Persistence of chlamydial
infection can lead to the continuous release of proinflammatory
cytokines from the epithelial cells which results in tissue damage.
On the other hand, immune responses have also been held respon-
sible for the tissue damage. Although IFN-γ+ CD4 T cells induce
immunity to chlamydial infection, they might have detrimental
effects on the primary site of infection resulting in collateral dam-
age (25). CD4 T cells producing IL-4 can elicit immunopathol-
ogy via suppression of protective responses (26). Autoreactive T
cells specific for Chlamydia and host proteins such as heat-shock
protein 60 have also been described, although the mechanism
of their development can be assigned to the phenomenon of
molecular mimicry (27). A reduced pathology in IL-knockout
(KO) mice, compared to the wild-type (WT), during Chlamydia-
infectedmice suggests a detrimental role for IL-10 in this infection
model (28, 29). Therefore, overt responses by immune cells can
culminate into pathology during chlamydial infection.
Anti-Chlamydial Host Immunity
Many studies in animal models and clinical settings have demon-
strated that T cells play a crucial role in control of chlamydial
infections. In genital infection of C. trachomatis, CD4+, but not
CD8+, T cells are indispensable for resolution of primary as well
as secondary infections (30–33). Similar function for CD4+ T
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cells has been described in C. muridarum, a mouse biovar of C.
trachomatis, and lung and genital tract infection (34). Although
both CD4+ and CD8+ T cells contribute to immunity to C.
pneumoniae lung infection, the predominant role is played by
CD8+ T cells (35). The type of T-cell immunity has a profound
effect on whether the infection is contained or culminates into
pathology. Th1/Tc1 responses characterized by IFN-γ produc-
tion by CD4+/CD8+ T cells are the major form of protective
immunity (34). It is also shown that IL-17/Th17, in cooperation
with Th1, responses exert anti-chlamydial adaptive immunity,
especially in lung infections (36–38). In contrast, Th2 immunity
characterized by secretion of cytokines such as IL-4, IL-5, and IL-
13 aremore associated with inflammatory and pathologic changes
(34). IL-10, a Th2 and immunoregulatory cytokine, has also been
annexed with pathologic responses (28). Therefore, promotion
of Th1/Tc1 and, in certain conditions, Th17 responses are more
likely beneficial for resolution of chlamydial infection, whilst the
increase of Th2 responses culminates into pathology.
Activation of iNKT Cells
Activation of iNKT cells is achieved through two mechanisms;
CD1d-dependent and CD1d-independent. In CD1d-independent
mechanism, iNKT cells are activated without involvement of
CD1d molecules. This type of activation is mediated through
innate or inflammatory stimuli irrespective of the presence of
foreign microbial antigens, possibly in conjunction with self-
glycolipid antigen recognition (39). Recent data further illustrate
that the innate stimuli such as cytokines appear to be the pre-
dominant means of iNKT-cell activation, even with bacteria that
carry iNKT cell agonists (40). On the other hand, in CD1d-
dependentmechanism, antigens are presented byCD1dmolecules
expressed on antigen-presenting cells (APCs) such as DCs for
interaction with iTCR that possesses a conformation that is able
to recognize glycolipid and lipid antigens processed and presented
to them by CD1d molecules (41, 42). Interaction between iTCR
and its cognate ligand leads to the activation of iNKT cells, as
evidenced by massive production of a variety of cytokines, such
as Th1 (IFN-γ), Th2 (IL-4), and Th17 (IL-17) cytokines and
chemokines (43). The biochemical and physiological nature of
iNKT-cell-specific ligands has been deciphered by many recent
studies. Kawano et al. for the first time identified a lipid antigen
specific for iNKT TCR, α-galactosylceramide (α-GalCer), which
was originally isolated from a marine sponge, Agelasmauritianus
(44). Since α-GalCer is a potent ligand for iNKT-cell activation
and has been instrumental in understanding the biological prop-
erties of iNKTcells, it is referred to as a prototypic antigen for these
cells. The ability to activate iNKT cells is however not limited to
α-GalCer. A variety of microbial antigens have also been shown
to activate iNKT cells, such as α-glucuronosylceramide from
Sphingomonas species (45–47), α-galactosyldiacylglycerol from
Borrelia burgdorferi (48), and phosphatidylinositol-mannosidase
fromMycobacterium bovis BCG (49, 50). In an attempt to identify
chlamydial lipid antigens which active iNKT cells, we tested a
previously reported glycolipid exoantigen from C. muridarum
(GLXA) for activation of iNKT cells (51, 52). We found that
intravenous injection of GLXA into WT mice led to an enhanced
production of IFN-γ and IL-4 in mouse sera, which was not seen
in Jα18-KO mice that lack iNKT cells only. Following GLXA
treatment, iNKT cells underwent activation and produced IFN-
γ and IL-4 (52). These findings suggest that chlamydial GLXA
acts as a specific ligand for iNKT-cell activation. In line with these
findings, Jiang et al., using APC-free culture system, have shown
that both iNKT as well as type II NKT-cell hybridomas were
activated when cultured with ultraviolet-killed C. muridarum
(53). It is known that iNKT and type II NKT cells are activated
by different ligands. For example, lipid and glycolipids are lig-
ands for iNKT-cell activation, whereas hydrophobic antigens such
as sulfatides induce specific activation of type II NKT but not
iNKT cells. Since C. muridarum activated iNKT and type II NKT
cell hybridomas, it is likely that there are different chlamydial
antigens for activating these cell types (53). Therefore, further
studies on identification and purification of different chlamydial
antigens for iNKT- and type II NKT-cell activation may be crucial
for anti-chlamydial vaccine development. Based on the current
data, it appears reasonable to conclude that iTCR is involved
in activation of iNKT cells through interaction with chlamydial
antigens.
iNKT Cells in Protective Immunity Against
Chlamydial Infection
Recent studies in mice have provided significant evidence on the
role of NKT cells in protective immunity to various infections,
including chlamydial infections (54, 55). Activation of iNKT cells
by injection of α-GalCer in mice mounted a strong protective
immunity to intranasal C. pneumoniae, intra-articular C. tra-
chomatis, and intravaginal C. muridarum infection (54, 56, 57).
In these studies, BALB/c mice were used for intra-articular C.
trachomatis and vaginal C. muridarum infection, and C57BL/6
mice for intranasal C. pneumoniae infection; however, the out-
comes of the infections were similar following α-GalCer treat-
ment (54, 56, 57). To better understand the protective function
of NKT cells in vivo during chlamydial infections, we and other
groups used various experimental approaches, including trans-
genic/KO mice. During C. trachomatis intra-articular infection,
CD1d-KO mice, which lack both iNKT and type II NKT cells,
experienced enhanced pathology and higher bacterial burden
compared to the WT mice, indicating a protective role for NKT
cells in this infection model (57). To directly examine the con-
tribution of iNKT cells in host defense against C. pneumoniae
infection, we infected Jα18-KO mice through intranasal route
(54). Upon infection challenge, more severe body weight loss,
pathological changes, and higher organism growth were observed
in Jα18-KO mice than in the WT mice (54), which suggested
a protective effect of iNKT-cell activation on C. pneumoniae
infection. We further assessed the impact of iNKT cells on T
cells in the context of cytokine response to C. pneumoniae infec-
tion (54). Intracellular cytokine analysis demonstrated that the
WT mice, compared to the KO, displayed a robust type-1 CD4
and CD8 T cell response, characterized by IFN-γ production
in C. pneumoniae infection. Furthermore, CD4 T cells of Jα18-
KO mice reflected an enhanced Th2 (IL-4) response than those
from the WT mice (54). Thus, iNKT cells contribute to the
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development of protective Th1/Tc1 responses against C. pneumo-
niae infection.
Bridging Innate and Adaptive Immunity
It is becoming clearer that innate and adaptive immune systems
do not work in isolation, but rather interact with each other
to give rise to an optimal immune response against infections.
A significant example in this context is the case of innate lym-
phocytes that have been shown to bridge innate and adaptive
immunity by modulating DCs (58). To study the impact of iNKT
cells on DC function, α-GalCer as a model antigen has been
widely used. Whether this is true in case of real infections has
been addressed by some recent studies (59–63). Our recent studies
using a mouse model of C. pneumoniae infection have done an
in-depth analysis of the impact of iNKT cells on DC function
for the elicitation of T-cell immunity in a real infection setting
(62, 63) (Figure 1). Adoptive transfer of DCs isolated from the
spleens of C. pneumoniae-infected Jα18-KO, in contrast to the
WT, mice promoted infection and pathology in naïve recipient
mice upon challenge with chlamydial infection (62), suggesting
that iNKT cells are crucial for DCs to confer protective Th1/Tc1
immunity. Overall, these data provided direct evidence on the
role of iNKT cells in modulating DC function thereby enhancing
protective immunity in an in vivo model of infection. Since DCs
demonstrate a high degree of heterogeneity consisting of various
subsets, we further investigated whether this modulating effect of
iNKT cells was biased to a DC subset. CD8α+ and CD8α  DCs
are important DC subsets residing in the lymphoid tissues such
as the spleen. While CD8α+DCs induce Th1 responses, CD8α 
DCs skew Th2 responses (64). These DC subsets were purified
from Jα18-KO and WT mice following chlamydial infection and
then adoptively transferred to naïve recipient mice that subse-
quently received chlamydial infection. While both the groups
of mice receiving CD8α+ and CD8α  DCs from WT mice
showed significant resistance to infection compared to those from
Jα18-KO mice, the WT CD8α+ DC recipients had superior
protection (63). Collectively, these data provided the first direct
evidence that iNKT cells preferentially promote the functional
development of a subset of DC to generate protective immunity
against infections. Since the local pulmonary immune responses
may not be similar to that in the splenic environment, we also
examined the iNKT cell–DC interaction in the lung, which is
the primary site of infection where predominant inflammatory
and immunologic changes occur (65). These findings, however,
were not different from what we observed in splenic DC stud-
ies, which suggested that DCs residing in different anatomical
compartments induce similar immune responses during chlamy-
dial lung infection. Apart fromDCs, alveolar macrophages (AMs)
are also a critical immune cell population in the lung that reg-
ulates immune responses against pulmonary pathogens. In C.
muridarum infection, iNKT cells were found to affect both the
phenotype as well as function of AMs (unpublished observa-
tion). Altogether, these findings suggest that iNKT cells exert
protective T-cell immunity to C. pneumoniae through modu-
lating the function of APCs. How do iNKT cells modulate the
DC function? In C. pneumoniae infection, the expression of
CD40L and IFN-γ by iNKT cells was found to be upregulated
(62). To directly examine the contribution of CD40L and IFN-
γ in the modulating effect of iNKT cells on DC, we cocultured
iNKT cells with DCs and then used blocking antibodies against
these molecules. Blockade of either CD40L or IFN-γ significantly
reduced the enhancing effect of iNKT cells on IL-12 produc-
tion by DCs. However, the enhanced effect on IL-12 production
was completely abrogated when physical contact between these
cells was prevented (62). These data conclude that CD40–CD40L
interaction, IFN-γ production, and cell-to-cell contact are criti-
cal for iNKT cells to modulate DC function during chlamydial
infection.
Recent reports indicate a modulating effect of NKT cells on the
function of NK cells. In vivo administration of α-GalCer in mice
induced NK cells to produce IFN-γ as well as cause cytotoxicity
(66, 67). Since NKT and NK cells have been shown to contribute
to immunity against chlamydial infections, we focused onwhether
NKT cells influence the functional role of NK cells during infec-
tion (68). We found a reduced expansion of NK cells in Jα18-KO
mice following C. muridarum infection. A lower percentage of
IFN-γ-producing, but higher CD107a+ degranulating, NK cells
were observed in Jα18-KO than in WT mice. These data suggest
that iNKT cells have a differential effect on NK cell functions.
They enhance IFN-γ production by NK cells but inhibit their
cytotoxic activities during chlamydial infection (68). Whether
the interaction between iNKT and NK cells shape the adaptive
immunity merits further exploration.
FIGURE 1 | Induction of anti-chlamydial T-cell responses by iNKT cells
through DC modulation. During chlamydial infections, iNKT cells induce DC
maturation through IFN-γ, CD40–CD40L binding, iTCR–Ag interaction, and
cell-to-cell contact. Once matured, DCs induce enhanced production of IL-12
that skews Th1/Tc responses. Th1/Tc responses characterized by IFN-γ
production lead to the clearance of intracellular Chlamydiae.
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iNKT Cells in Chlamydial Pathology
Although a growing wealth of evidence indicates a protective
role for iNKT cells in chlamydial infections, some studies have
implicated them in eliciting pathologic responses (53, 54, 69).
In vivo stimulation of iNKT cells by α-GalCer increased C.
muridarum burden in the lungs of BALB/c mice (69). However,
following C. muridarum lung infection, CD1d-KO mice (BALB/c
background) displayed reduced body weight loss, lung pathology,
and chlamydial growth compared to WT mice, which suggested
that NKT cells induce immunopathology to C. muridarum (69).
Similar pathogenic effects of NKT-cell activation were recorded in
response tomurine genital tract infectionwithC.muridarum (53).
When challenged with genital C. muridarum infection, WT mice
exhibited severe pathologic changes such as oviduct dilation and
fibrosis compared to the CD1d-KO mice (53). Altogether these
findings suggested a promoting effect of NKT, including iNKT
cell, activation on C. muridarum infection, which is in contrast to
their protective role in C. pneumoniae infection (54). The reason
behind why iNKT cells act differently in the outcome of infection
with these two chlamydial species is still unclear and so warrants
further investigation. It appeared that while both pathogens share
many biological features, the cellular response and immunological
course during infection are different in addition to the differ-
ences in growth characteristics and host specificity of these two
pathogens. In broad sense, these results suggest that NKT-cell
activation effect or the activation itself is pathogen or even species
specific. Since Chlamydiae may have various antigens for iNKT
cells, it is possible that the antigenic variability among the antigens
from different chlamydial strains might explain the differential
iNKT-cell responses. It is also possible that NKT cells including
iNKT cells can play variable roles in different conditions or stages
of infection, same as other cell types like CD4 and CD8 T cells. On
the other hand, the detrimental role of NKT cells in chlamydial
infection has been mostly reported in the studies using CD1d-
KO mice that are in BALB/c background and have deficiency
in both iNKT and type II NKT cells. Therefore, the observed
distinction between chlamydial strains should be more carefully
studied. In addition, in-depth studies on the characterization of
glycolipid antigens derived from different chlamydial species and
analyses of iNKT-cell activation effects in different routes and
stages/conditions of infection would provide more insight into
the iNKT-cell-mediated pathologic mechanisms in chlamydial
infection.
NKT-Cell Subsets in Chlamydial Infections
Invariant NKT and type II NKT cells have distinct characteristics
for their phenotype and function. Whether these cell subsets
induce differential immune responses to chlamydial infections
is not fully understood. To elucidate the specific roles of iNKT
and type II cells in anti-chlamydial immunity, we used CD1d-KO
and Jα18-KO mice because the former lack both iNKT and type
II NKT cells but the latter are deficient in only iNKT cells. We
found that CD1d-KO, in contrast to WT, mice showed increased
resistance to C. muridarum lung infection. Similar outcome of
C. muridarum infection was found in case of Jα18-KO. These
findings indicate a detrimental role for both iNKT and type II
NKT cells in C. muridarum infection (54, 69). On the contrary,
CD1d-KO and Jα18-KO mice displayed increased susceptibility
to C. pneumoniae lung infection compared to their respective
WT control mice (54), which advocates that NKT-cell subsets
induce protection. Taking account of these data, it appears that
the protective or pathogenic roles of NKT-cell subsets are mainly
driven by the type of bacterial species used to infect mice. Of
note, CD1d-KO and Jα18-KO mice used in these studies were
having BALB/c and C57BL/6 genetic backgrounds, respectively.
Since the outcome of chlamydial infection might be impacted
by genetic differences, it would be prudent to use different KO
mice with similar genetic background to arrive at a definitive
conclusion.
In contrast to the immune function of NKT-cell subsets in
chlamydial infections, iNKT and type II NKT cells have been
shown to have differential impact on the outcome in certain
other models, especially for anti-tumor immunity. In vitro stim-
ulation of murine and human iNKT cells with α-GalCer led to
an enhanced lysis of tumor cells in a perforin- and granzyme B-
dependent fashion, which suggested a direct protective role of
these cells in tumor lysis (70, 71). Using a methylcholanthrene
(MCA)-induced fibrosarcoma mouse model, Smyth et al. showed
that Jα18-KO mice treated with different doses of MCA devel-
oped fibrosarcoma, while the control B6 mice did not develop
tumors (72). Upon adoptive transfer of the liver lymphocytes from
WT mice, Jα18-KO mice, when injected with MCA, exhibited
enhanced protection against tumor growth compared to the Jα18-
KO mice that received either the liver lymphocytes from Jα18-
KO mice or PBS (73). These findings indicate a clear role for
iNKT cells in protective immunity to tumor development. In
contrast to the anti-tumor activities of iNKT cells, type II NKT
cells are reported to suppress the tumor immunosurveillance (74,
75). CD1d-KO, in contrast to Jα18-KO and WT, mice promoted
the growth of subcutaneous 15-12RM fibrosarcoma and CT26-L5
colon carcinoma, which indicates that type II NKT cells inhibit
the tumor immunosurveillance (74). Similarly, type II NKT cells
were suppressive in the immune responses to B-cell lymphomas
(75). Overall, these data point out that iNKT cells confer pro-
tective immunity to tumors, whereas type II NKT cells promote
pathology. In a broader perspective, the data from chlamydial
infection and tumor models shed significant light on different
roles played by iNKT and type II NKT cells in diverse dis-
ease settings. This emphasizes the careful analysis of the impact
of NKT-cell subsets on the outcome of diseases because find-
ings from one experimental model cannot be extrapolated to
another.
Conclusion and Future Directions
Invariant NKT cells play an important role in immunity
to chlamydial infections. These cells not only induce innate
responses but also shape adaptive responses, bridging innate and
adaptive immunity. In doing so, iNKT cells modulate the function
of DCs through enhanced cytokine production, CD40–CD40L
binding, iTCR–antigen interaction, and cell-to-cell contact. In
addition, iNKT cells can modulate the function of NK cells
that can also modulate DC function. While significant insights
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have been provided toward understanding the iNKT-cell biology
in chlamydial infections, the following questions need to be
addressed in the times to come.
(1) The involvement of iNKT cells in both protective immunity
and pathology in chlamydial infections has been reported.
Notably, the protective and detrimental role of NKT cells
in chlamydial infection was mostly shown in Jα18-KO and
CD1d-KO mice, respectively. Considering the differences of
the mice in genetic background (C57BL/6 vs. BALB/c) and
NKT cells (iNKTonly vs. iNKT and type IINKT cells), amore
detailed study to exclude the influences of these variations
need to be performed.
(2) The molecular basis for the influence of iNKT cells on spleen
and lung DCs need to be studied in-depth. In addition, it
would be interesting to see if there is any impact of iNKT cells
on the migration pattern of DC/DC subsets, which is crucial
for priming T cells in the lymphoid tissues.
(3) The impact of iNKT cells on other immune cells, apart
from NK cells and DCs, merits further investigation. For
example, AMs are considered to be a critical immune cell
population in pulmonary pathogen defense. How do iNKT
cells modulate AMs to influence the outcome of chlamydial
infection?
(4) How to prophylactically and therapeutically target iNKT cells
for inducing protection without having any significant side
effects? Can chlamydial lipid antigens be used in vaccine
design strategies for promoting DC function?
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